CCUS Clonal Cytopenia of Undetermined Significance
6
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Dresden MDS Registry With an Accompanying Biomaterial Collection
Luspatercept for Clonal Cytopenias of Uncertain Significance
CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research
Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance